Published in J Clin Invest on July 01, 1995
Expression and localization of macrophage elastase (matrix metalloproteinase-12) in abdominal aortic aneurysms. J Clin Invest (1998) 2.43
Angiotensin II increases urokinase-type plasminogen activator expression and induces aneurysm in the abdominal aorta of apolipoprotein E-deficient mice. Am J Pathol (2001) 1.48
Impaired arterial neointima formation in mice with disruption of the plasminogen gene. J Clin Invest (1997) 1.44
Biomarkers of abdominal aortic aneurysm progression. Part 2: inflammation. Nat Rev Cardiol (2009) 1.17
An endothelial storage granule for tissue-type plasminogen activator. J Cell Biol (1997) 1.10
Digging in the "soil" of the aorta to understand the growth of abdominal aortic aneurysms. Vascular (2009) 0.92
Mechanisms of urokinase plasminogen activator (uPA)-mediated atherosclerosis: role of the uPA receptor and S100A8/A9 proteins. J Biol Chem (2011) 0.88
Increased PAI-1 in females compared with males is protective for abdominal aortic aneurysm formation in a rodent model. Am J Physiol Heart Circ Physiol (2012) 0.85
Locally applied leptin induces regional aortic wall degeneration preceding aneurysm formation in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol (2012) 0.84
Role of plasminogen activator inhibitor in the reciprocal regulation of bovine aortic endothelial and smooth muscle cell migration by TGF-beta 1. Am J Pathol (1996) 0.83
Patterns of expression of fibrinolytic genes and matrix metalloproteinase-9 in dissecting aortic aneurysms. Am J Pathol (1998) 0.83
Plasmin promotes foam cell formation by increasing macrophage catabolism of aggregated low-density lipoprotein. Arterioscler Thromb Vasc Biol (2013) 0.78
Expression profiles of fibrinolytic components in nasal mucosa. Histochem Cell Biol (2004) 0.77
The study of t-PA, u-PA and PAI-1 genes polymorphisms in patients with abdominal aortic aneurysm. Mol Biol Rep (2014) 0.75
The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature (1993) 27.07
Angiogenic factors. Science (1987) 15.22
Secretory products of macrophages. J Clin Invest (1987) 10.33
Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res (1985) 8.64
Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation (1994) 6.03
Intimal vascularization and atherosclerosis. J Pathol Bacteriol (1951) 5.03
Human atherosclerosis. II. Immunocytochemical analysis of the cellular composition of human atherosclerotic lesions. Am J Pathol (1986) 4.51
Hypothesis: vasa vasorum and neovascularization of human coronary arteries. A possible role in the pathophysiology of atherosclerosis. N Engl J Med (1984) 3.41
Biochemical interactions of tumor cells with the basement membrane. Annu Rev Biochem (1986) 3.06
Endothelial cell markers CD31, CD34, and BNH9 antibody to H- and Y-antigens--evaluation of their specificity and sensitivity in the diagnosis of vascular tumors and comparison with von Willebrand factor. Mod Pathol (1994) 2.77
The pathogenesis of atherosclerosis: atherogenesis and inflammation. Lab Invest (1988) 2.68
Elastase-induced experimental aneurysms in rats. Circulation (1990) 2.50
Detection and localization of tumor necrosis factor in human atheroma. Am J Cardiol (1990) 2.22
Atherosclerotic plaque caps are locally weakened when macrophages density is increased. Atherosclerosis (1991) 2.10
Human abdominal aortic aneurysms. Immunophenotypic analysis suggesting an immune-mediated response. Am J Pathol (1990) 1.88
Cloning and sequence of a cDNA coding for the human beta-migrating endothelial-cell-type plasminogen activator inhibitor. Proc Natl Acad Sci U S A (1986) 1.85
Membrane and matrix localization of proteinases: a common theme in tumor cell invasion and angiogenesis. Biochim Biophys Acta (1988) 1.82
The structure of the human tissue-type plasminogen activator gene: correlation of intron and exon structures to functional and structural domains. Proc Natl Acad Sci U S A (1984) 1.82
Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin). J Biol Chem (1988) 1.77
Relationship between tissue plasminogen activator and the activators in blood and vascular wall. Thromb Res (1980) 1.76
Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci U S A (1992) 1.76
Comparison of abdominal and thoracic aortic medial structure in mammals. Deviation of man from the usual pattern. Circ Res (1969) 1.74
Cellular localization of type 1 plasminogen activator inhibitor messenger RNA and protein in murine renal tissue. Am J Pathol (1993) 1.52
The role of plasminogen activators in the regulation of connective tissue metalloproteinases. Ann N Y Acad Sci (1992) 1.48
Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries. Arterioscler Thromb (1993) 1.38
Production of tumor necrosis factor and interleukin-1 by macrophages from human atheromatous plaques. Am J Pathol (1993) 1.30
Correlation of inflammatory infiltrate with the enlargement of experimental aortic aneurysms. J Vasc Surg (1992) 1.29
Carotid plaque hemorrhage. Its role in production of cerebral ischemia. Arch Surg (1982) 1.24
In vivo patterns of expression of urokinase and its inhibitor PAI-1 suggest a concerted role in regulating physiological angiogenesis. Proc Natl Acad Sci U S A (1992) 1.23
Identification of matrix metalloproteinases 3 (stromelysin-1) and 9 (gelatinase B) in abdominal aortic aneurysm. Arterioscler Thromb (1994) 1.23
Purification of a protein from bovine plasma that binds to type 1 plasminogen activator inhibitor and prevents its interaction with extracellular matrix. Evidence that the protein is vitronectin. J Biol Chem (1989) 1.20
Collagenase activity of the human aorta. A comparison of patients with and without abdominal aortic aneurysms. Arch Surg (1980) 1.09
Immunoelectron-microscopic localization of S-protein/vitronectin in human atherosclerotic wall. Atherosclerosis (1989) 1.01
Cellular, enzymatic, and genetic factors in the pathogenesis of abdominal aortic aneurysms. J Vasc Surg (1989) 0.97
Angiogenic activity of the atherosclerotic carotid artery plaque. J Neurosurg (1989) 0.95
Neovascularization and coronary atherosclerotic plaque: cinematographic localization and quantitative histologic analysis. Hum Pathol (1987) 0.93
Expression of basic and acidic fibroblast growth factors and their receptor in normal and atherosclerotic human arteries. Cardiovasc Res (1993) 0.93
Abnormal expression of plasminogen activators in aortic aneurysmal and occlusive disease. J Vasc Surg (1994) 0.88
In vivo demonstration of focal fibrinolytic activity in abdominal aortic aneurysms. Eur J Vasc Surg (1993) 0.88
Immunohistochemical localization of S protein/vitronectin in human atherosclerotic versus arteriosclerotic arteries. Virchows Arch A Pathol Anat Histopathol (1989) 0.88
Sustained arterial injury and progression of atherosclerosis. Ann N Y Acad Sci (1990) 0.86
Possible key role for plasmin in the pathogenesis of abdominal aortic aneurysms. Surgery (1994) 0.86
Thromboplastic and fibrinolytic activity of the arteriosclerotic human aorta. Nature (1962) 0.85
Increased collagenase activity in early aneurysmal dilatation. J Vasc Surg (1986) 0.78
An assay for transforming growth factor-beta using cells transfected with a plasminogen activator inhibitor-1 promoter-luciferase construct. Anal Biochem (1994) 6.31
Programmable and autonomous computing machine made of biomolecules. Nature (2001) 3.51
Bacterial lipopolysaccharide and inflammatory mediators augment IL-6 secretion by human endothelial cells. J Immunol (1989) 3.01
Synthesis of a fibrinolytic activator and inhibitor by endothelial cells. Proc Natl Acad Sci U S A (1977) 2.83
Concern about safety of carotid angioplasty. Stroke (1996) 2.73
Identification of regulatory sequences in the type 1 plasminogen activator inhibitor gene responsive to transforming growth factor beta. J Biol Chem (1991) 2.52
Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. J Biol Chem (1985) 2.23
Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelial cells. J Biol Chem (1984) 2.22
Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J Cell Biol (1996) 2.21
Detection of an unusually stable fibrinolytic inhibitor produced by bovine endothelial cells. Proc Natl Acad Sci U S A (1983) 2.20
Real-time color duplex scanning after sclerotherapy of the greater saphenous vein. J Vasc Surg (1991) 2.10
Cytokine activation of vascular endothelium. Effects on tissue-type plasminogen activator and type 1 plasminogen activator inhibitor. J Biol Chem (1988) 2.04
Palmar hyperhidrosis and its surgical treatment: a report of 100 cases. Ann Surg (1977) 1.97
Regulation of mRNAs for type-1 plasminogen activator inhibitor, fibronectin, and type I procollagen by transforming growth factor-beta. Divergent responses in lung fibroblasts and carcinoma cells. J Biol Chem (1988) 1.93
Regulation of type 1 plasminogen activator inhibitor gene expression in cultured bovine aortic endothelial cells. Induction by transforming growth factor-beta, lipopolysaccharide, and tumor necrosis factor-alpha. J Biol Chem (1989) 1.92
Elevated expression of transforming growth factor-beta in adipose tissue from obese mice. Mol Med (1997) 1.92
Fatal complications of central venous catheters. Br Med J (1971) 1.92
Regulation of the fibrinolytic system of cultured human vascular endothelium by interleukin 1. J Clin Invest (1986) 1.89
Current status of noninvasive tests in the diagnosis of peripheral arterial disease. Surg Clin North Am (1982) 1.87
Cloning and sequence of a cDNA coding for the human beta-migrating endothelial-cell-type plasminogen activator inhibitor. Proc Natl Acad Sci U S A (1986) 1.85
Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta. J Clin Invest (1991) 1.85
Cellular sensitivity to collagen in thromboangiitis obliterans. N Engl J Med (1983) 1.79
Cultured bovine endothelial cells produce both urokinase and tissue-type plasminogen activators. J Cell Biol (1982) 1.77
Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci U S A (1992) 1.76
Computed tomography scanning findings associated with rapid expansion of abdominal aortic aneurysms. J Vasc Surg (1994) 1.72
Bacteriophage-T7-induced DNA-priming protein. A novel enzyme involved in DNA replication. Eur J Biochem (1977) 1.69
Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo. Induction by tumor necrosis factor-alpha and lipopolysaccharide. J Clin Invest (1996) 1.65
Anti-Escherichia coli adhesin activity of cranberry and blueberry juices. N Engl J Med (1991) 1.64
Type 1 plasminogen activator inhibitor gene: functional analysis and glucocorticoid regulation of its promoter. Proc Natl Acad Sci U S A (1988) 1.64
Gly369Cys mutation in mouse FGFR3 causes achondroplasia by affecting both chondrogenesis and osteogenesis. J Clin Invest (1999) 1.62
Reverse fibrin autography: a method to detect and partially characterize protease inhibitors after sodium dodecyl sulfate--polyacrylamide gel electrophoresis. Anal Biochem (1984) 1.59
Transcutaneous PO2 measurements in health and peripheral arterial occlusive disease. Surgery (1982) 1.54
Activation of rabbit Hageman factor by homogenates of cultured rabbit endothelial cells. J Clin Invest (1980) 1.53
Cellular localization of type 1 plasminogen activator inhibitor messenger RNA and protein in murine renal tissue. Am J Pathol (1993) 1.52
Changes in procoagulant and fibrinolytic gene expression during bleomycin-induced lung injury in the mouse. J Clin Invest (1995) 1.52
Guidelines for carotid endarterectomy. A multidisciplinary consensus statement from the ad hoc Committee, American Heart Association. Stroke (1995) 1.51
Detection and partial characterization of an inhibitor of plasminogen activator in human platelets. J Clin Invest (1984) 1.50
Type 1 plasminogen activator inhibitor. Prog Hemost Thromb (1989) 1.49
Early reoperation for perirectal abscess: a preventable complication. Dis Colon Rectum (2001) 1.49
Delayed presentation of carotid intimal tear following blunt craniocervical trauma. Surgery (1974) 1.47
Effects of intraaortic balloon counterpulsation on the severity of myocardial ischemic injury following acute coronary occlusion. Counterpulsation and myocardial injury. Circulation (1972) 1.46
Murine CD14 gene expression in vivo: extramyeloid synthesis and regulation by lipopolysaccharide. J Exp Med (1995) 1.46
The primary plasminogen-activator inhibitors in endothelial cells, platelets, serum, and plasma are immunologically related. Proc Natl Acad Sci U S A (1985) 1.46
Murine tissue factor gene expression in vivo. Tissue and cell specificity and regulation by lipopolysaccharide. Am J Pathol (1993) 1.45
Inhibitory activity of cranberry juice on adherence of type 1 and type P fimbriated Escherichia coli to eucaryotic cells. Antimicrob Agents Chemother (1989) 1.45
Tissue factor gene expression in the adipose tissues of obese mice. Proc Natl Acad Sci U S A (1998) 1.44
Adaptations of the left ventricle to chronic pressure overload. Circ Res (1976) 1.44
An open-label pilot trial of cladibrine (2-cholordeoxyadenosine) in patients with primary sclerosing cholangitis. J Clin Gastroenterol (2000) 1.42
Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity. J Clin Invest (2001) 1.41
Plasminogen activator inhibitor-1 and its cofactor vitronectin stabilize arterial thrombi after vascular injury in mice. Circulation (2001) 1.39
The transmembrane mutation G380R in fibroblast growth factor receptor 3 uncouples ligand-mediated receptor activation from down-regulation. Mol Cell Biol (2000) 1.38
Rapid loss of microvascular integrin expression during focal brain ischemia reflects neuron injury. J Cereb Blood Flow Metab (2001) 1.37
The treatment of coronary occlusive disease by endarterectomy. J Thorac Cardiovasc Surg (1965) 1.32
Structural and functional analysis of the plasminogen activator inhibitor-1 binding motif in the somatomedin B domain of vitronectin. J Biol Chem (1996) 1.31
Kaposi's sarcoma in immunosuppression. Possibly the result of a dual viral infection. Cancer (1990) 1.31
Fibrin deposition in tissues from endotoxin-treated mice correlates with decreases in the expression of urokinase-type but not tissue-type plasminogen activator. J Clin Invest (1996) 1.29
Tissue distribution and regulation of murine von Willebrand factor gene expression in vivo. Blood (1998) 1.29
Distinct antithrombotic consequences of platelet glycoprotein Ibalpha and VI deficiency in a mouse model of arterial thrombosis. J Thromb Haemost (2006) 1.28
Activated protein C stimulates the fibrinolytic activity of cultured endothelial cells and decreases antiactivator activity. Proc Natl Acad Sci U S A (1985) 1.27
Human melanoma cells derived from lymphatic metastases use integrin alpha v beta 3 to adhere to lymph node vitronectin. J Clin Invest (1992) 1.26
The fibrinolytic system of the vascular wall. Clin Haematol (1985) 1.25
Tissue distribution of factor VIII gene expression in vivo--a closer look. Thromb Haemost (2001) 1.24
Plasminogen activator inhibitor-1 regulates cell adhesion by binding to the somatomedin B domain of vitronectin. J Cell Physiol (2001) 1.23
Tumor necrosis factor alpha is a key component in the obesity-linked elevation of plasminogen activator inhibitor 1. Proc Natl Acad Sci U S A (1999) 1.23
Comparative studies of the fibrinolytic activity of cultured vascular cells. Thromb Res (1979) 1.22
Type I procollagen C-proteinase from mouse fibroblasts. Purification and demonstration of a 55-kDa enhancer glycoprotein. Eur J Biochem (1989) 1.21
Evidence that type 1 plasminogen activator inhibitor binds to the somatomedin B domain of vitronectin. J Biol Chem (1991) 1.21
Role of vitronectin and its receptors in haemostasis and vascular remodeling. Thromb Res (1998) 1.21
Coordinated induction of plasminogen activator inhibitor-1 (PAI-1) and inhibition of plasminogen activator gene expression by hypoxia promotes pulmonary vascular fibrin deposition. J Clin Invest (1998) 1.20
Purification of a protein from bovine plasma that binds to type 1 plasminogen activator inhibitor and prevents its interaction with extracellular matrix. Evidence that the protein is vitronectin. J Biol Chem (1989) 1.20
Extracellular matrix of cultured bovine aortic endothelial cells contains functionally active type 1 plasminogen activator inhibitor. Blood (1987) 1.20
Effect of thrombin on the fibrinolytic activity of cultured bovine endothelial cells. J Clin Invest (1979) 1.20
Growth rates of small abdominal aortic aneurysms. Surgery (1976) 1.20
Treatment of basal cell carcinoma with intralesional interferon. J Am Acad Dermatol (1986) 1.19
Tissue factor expression during human and mouse development. Am J Pathol (1996) 1.19
The somatomedin B domain of vitronectin. Structural requirements for the binding and stabilization of active type 1 plasminogen activator inhibitor. J Biol Chem (1994) 1.18
Experimental and clinical experience with transcutaneous Doppler ultrasonic flowmeters. Arch Surg (1970) 1.17
Ultrasonic detection and evaluation of abdominal aortic aneurysms. Surgery (1972) 1.15
Mechanism of protein C-dependent clot lysis: role of plasminogen activator inhibitor. Blood (1986) 1.15
FGF receptors ubiquitylation: dependence on tyrosine kinase activity and role in downregulation. FEBS Lett (2002) 1.14
Guidelines for carotid endarterectomy. A multidisciplinary consensus statement from the Ad Hoc Committee, American Heart Association. Circulation (1995) 1.13
Molecular mechanisms of cutaneous aging: connective tissue alterations in the dermis. J Investig Dermatol Symp Proc (1998) 1.13
Human endothelial cells produce IL-6. Lack of responses to exogenous IL-6. Ann N Y Acad Sci (1989) 1.12
Replication of dengue and junin viruses in cultured rabbit and human endothelial cells. Infect Immun (1978) 1.12
Distribution and symmetry of arteriosclerotic lesions of the lower extremities: an arteriographic study of 200 limbs. Cardiovasc Intervent Radiol (1985) 1.12
Gene expression during the development of Bacillus subtilis bacteriophage phi29. II. Resolution of viral-specific ribonucleic acid molecules. J Virol (1973) 1.12
Serum-mediated suppression of cell-associated plasminogen activator activity in cultured endothelial cells. Cell (1980) 1.11
DNA scission after focal brain ischemia. Temporal differences in two species. Stroke (1997) 1.11
Tissue distribution and regulation of plasminogen activator inhibitor-1 in obese mice. Mol Med (1996) 1.10
Immunoradiometric assay to measure the binding of a specific inhibitor to tissue-type plasminogen activator. J Lab Clin Med (1985) 1.09
Detection of vitronectin mRNA in tissues and cells of the mouse. Proc Natl Acad Sci U S A (1991) 1.09